Skip to main content
. 2023 Jul 31;11:1218670. doi: 10.3389/fchem.2023.1218670

TABLE 2.

Other prominent 177Lu-based radiopharmaceuticals under investigation not included in the clinical trials search and their targets.

Radiopharmaceutical Target Treatment conditions
177Lu-DOTA.SA.FAPi FAP Solid tumors
177Lu-DOTAGA.(SA.FAPi)2 FAP Solid tumors
177Lu-FAPi-46 FAP Solid tumors
177Lu-trastuzumab HER2 Breast Cancer
177Lu-brentuximab CAIX Hypoxic tumors
177Lu-PP-F11N CCK2R Medullary Thyroid Cancer